Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow Health (NASDAQ: HROW) has priced its underwritten public offering of $17.5 million in 8.625% senior notes due 2026. The offering, expected to close on June 17, 2021, may increase by $2.5 million if the underwriters exercise their option. The notes will be priced at $25.75 each, yielding aggregate proceeds of $18,025,000. Proceeds will be utilized to redeem Series B Cumulative Preferred Stock and support general corporate purposes. Both the new and existing notes are rated 'BB' by Egan-Jones Ratings Company and will trade on Nasdaq under the symbol 'HROWL'.
Harrow Health (NASDAQ: HROW) has initiated an underwritten registered public offering of $17.5 million in 8.625% senior notes due 2026. These notes will trade alongside the existing notes of the same series. The proceeds are intended to redeem all outstanding Series B Cumulative Preferred Stock and for general corporate purposes, including product acquisitions and capital expenditures. Harrow Health's notes received a 'BB' rating from Egan-Jones Ratings Company. The offering will be conducted under the effective shelf registration statement filed with the SEC.
Harrow Health (NASDAQ: HROW), an ophthalmic-focused healthcare company, has launched a redesigned corporate and investor website aimed at enhancing user experience and accessibility of historical and current information. The site showcases Harrow's journey as a leading eye health provider, featuring its mission, product pipeline, and commitment to accessible eyecare. Key assets include ImprimisRx and Visionology, along with equity stakes in several pharmaceutical companies. The site also includes Letters to Stockholders and a Corporate Presentation to facilitate investor engagement.
Harrow Health, Inc. (NASDAQ: HROW) announced a multi-center retrospective study demonstrating significant improvements in patients with dry eye disease using its Klarity-C Drops® (cyclosporine 0.1%). Published in Clinical Ophthalmology, the study involved 50 patients and showed a marked decrease in ocular surface disease index (OSDI) scores and corneal staining grades after three months of treatment. The study highlighted no adverse events and emphasized Klarity-C's advantages over existing treatments, including its affordability and lack of insurance hurdles.
Harrow Health reported record first-quarter 2021 results, achieving revenues of $15.4 million, up 31% from $11.8 million year-over-year. Adjusted EBITDA reached $4.3 million, significantly higher than the previous year's $0.4 million. Segment contribution from ImprimisRx rose to $5.7 million, while DEXYCU® sales commissions increased 39% over Q4 2020, totaling $485,000. GAAP operating income improved to $2.9 million from an operating loss of $0.6 million, and gross margins increased to 75.6%, compared to 69% last year.
Harrow Health (NASDAQ: HROW) announced the completion of a private sale of 440,000 shares of Series B Cumulative Preferred Stock, raising approximately $10.67 million. The funds will support general corporate purposes, including strategic product acquisitions and working capital. CEO Mark L. Baum highlighted that this transaction, along with previous fund raises totaling over $75 million in 2021, strengthens the company’s financial position for pursuing FDA-approved ophthalmic drug candidates. Harrow's focus remains on growth in the ophthalmic healthcare sector.
Harrow Health, Inc. (NASDAQ: HROW) announced the closing of an additional $5 million in 8.625% senior notes due 2026, following the exercise of the underwriters’ option from a previous $50 million offering. The total gross proceeds from this issuance amount to $55 million before fees. The additional notes will trade under the symbol HROWL. Funds will be allocated for general corporate purposes, including product acquisitions and capital expenditures. Both the notes and additional notes received a 'BB' rating from Egan-Jones Ratings Company.
Harrow Health, Inc. (NASDAQ: HROW) will announce its Q1 2021 financial results on May 11, 2021, after market close. The company specializes in ophthalmology and will provide a business update during a conference call at 4:45 p.m. ET on the same day. Investors can access the call details and results on the company’s website. Harrow Health owns ImprimisRx and Visionology, and holds substantial equity in Eton Pharmaceuticals and others. For more details, visit harrowinc.com.
Harrow Health (NASDAQ: HROW) has successfully closed a public offering of $50 million in senior notes, yielding approximately $48 million in net proceeds. The 8.625% senior notes, due in 2026, are set to trade on Nasdaq under the symbol 'HROWL'. Funds will primarily be used to repay $15.5 million of existing debt, with remaining proceeds allocated for general corporate purposes, including strategic acquisitions and working capital. The offering was rated 'BB' by Egan-Jones Ratings Company, enhancing investor confidence.
Harrow Health, an ophthalmic healthcare company, announced a public offering of $50 million in senior notes with an interest rate of 8.625%, due in 2026. The offering is expected to close on April 20, 2021, with a potential additional $5 million from underwriters. Proceeds will be used to repay $15.5 million in existing borrowings and fund general corporate purposes, including strategic acquisitions. The notes, rated 'BB,' will be listed on Nasdaq under the symbol 'HROWL.' The offering follows the company's SEC-approved shelf registration statement.